Early clinical remission and normalisation of CRP are the strongest predictors of efficacy, mucosal healing and dose escalation during the first year of adalimumab therapy in Crohn's disease

Clicks: 306
ID: 270102
2011
Free PDF
Article Quality & Performance Metrics
Overall Quality Improving Quality
0.0 /100
Combines engagement data with AI-assessed academic quality
AI Quality Assessment
Not analyzed
Abstract
Clinical efficacy and normalised CRP at week 12 (early deep clinical remission) are associated with medium-term clinical efficacy and mucosal healing during adalimumab therapy, whereas need for combined immunosuppression at induction and smoking status are predictors for non-response. Parallel azath …
Reference Key
ls2011alimentaryearly Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Kiss LS;Szamosi T;Molnar T;Miheller P;Lakatos L;Vincze A;Palatka K;Barta Z;Gasztonyi B;Salamon A;Horvath G;Tóth GT;Farkas K;Banai J;Tulassay Z;Nagy F;Szenes M;Veres G;Lovasz BD;Vegh Z;Golovics PA;Szathmari M;Papp M;Lakatos PL; ;;
Journal alimentary pharmacology & therapeutics
Year 2011
DOI
DOI not found
URL
https://www.pubmed.gov/21883326/
Keywords
National Center for Biotechnology Information NCBI NLM MEDLINE humans pubmed abstract nih national institutes of health national library of medicine logistic models treatment outcome adult female male young adult Remission Induction Prospective Studies Antibodies Monoclonal follow-up studies intestinal mucosa / immunology time factors dose-response relationship drug predictive value of tests crohn disease / drug therapy* anti-inflammatory agents / administration & dosage* intestinal mucosa / drug effects* adalimumab c-reactive protein / metabolism* humanized / administration & dosage* investigators=[] affs=[]) pmid:21883326 doi:10.1111/j.1365-2036.2011.04827.x l s kiss t szamosi collabauthor(name='hungarian ibd study group' crohn disease / blood

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.